跳至主要内容
临床试验/NCT01305564
NCT01305564已完成不适用

A Prospective, Multi-Center Study of the Bard® Denali™ Retrievable Inferior Vena Cava Filter

C. R. Bard44 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2011年6月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
200
试验地点
44
主要终点
Technical Success of Placement

研究概览

简要总结

The Bard® Denali™ Retrievable Inferior Vena Cava (IVC) study is a prospective, multi-center study which is intended to provide evidence of safety of the placement and retrieval of the Bard® Denali™ Retrievable Inferior Vena Cava Filter in subjects requiring IVC interruption to protect against pulmonary embolism (PE).

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
21 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • The subject or their legally authorized representative demonstrates understanding of the nature of the study and voluntarily provides written informed consent prior to any data collection or study procedures.
  • The subject is ≥ 21 years old, must be either a male or non-pregnant female with an expected lifespan sufficient to allow for completion of all study procedures. A negative pregnancy test result (urine or blood) is required prior to implant. If an enrolled female becomes pregnant prior to study completion, participation in the study will be terminated.
  • Based on Investigator judgment, the subject is at increased risk of PE requiring vena caval interruption. Note: Subjects diagnosed with acute DVT and/or PE must have objective confirmation based on imaging evidence of at least one of those diagnoses.
  • Patients without PE or venous thromboembolic disease (VTED) who are at risk of PE may be enrolled in this trial. However, enrollment of these patients will be limited to a maximum of 40% of the total sample size.
  • Based on Investigator's judgment, the subject has patent venous anatomy suitable for femoral or jugular/subclavian access for filter placement (e.g. no excessive tortuosity).
  • The IVC is ≤ 28 mm in diameter at the intended implantation site based on radiographic imaging evidence.
  • Based on Investigator's judgment, the filter can be safely placed such that the position of the filter tip is 1 cm below the lowest renal vein.
  • Retrieval of the filter is expected within 180 days post placement. At the six month follow up, if the Investigator determines that the filter continues to be clinically indicated, the filter may be left in place until the risk of PE has passed or left in permanently. All patients not having their filter retrieved at six months will continue be followed to 24 months or one month post filter retrieval, whichever comes first.
  • The subject has patent venous anatomy suitable for jugular access for retrieval of the filter based on imaging evidence within 48 hours prior to the filter placement procedure. Imaging mode will be at physician's discretion.
  • The subject is willing to comply with the protocol requirements and specified follow-up evaluations.

排除标准

  • The subject has a previously implanted filter in the IVC or superior vena cava (SVC).
  • The subject has a duplicated or left-sided IVC.
  • The subject has a severe spinal deformity that would impede access to the IVC for the filter placement or filter retrieval procedures.
  • The subject has a serum creatinine ≥ 2 mg/dl (and not on dialysis) within seven days of study enrollment. Patients on dialysis are allowed to participate in this trial.
  • The subject has a known uncorrectable bleeding diathesis or active coagulopathy.
  • The subject has a life expectancy of < 25 months.
  • The subject has a known allergy or sensitivity to nickel or titanium.
  • The subject has a known allergy or sensitivity to iodinated contrast media, which cannot be adequately pre-medicated. NOTE: Alternative contrast agents are not permitted for the purposes of this study.
  • The subject is currently participating in an investigational drug or another device study.

结局指标

主要结局

Technical Success of Placement

时间窗: 6 months

Technical success of filter placement is defined as the deployment of the filter such that the physician judges the location to be suitable to provide sufficient mechanical protection against Pulmonary Embolism.

Clinical Success of Placement

时间窗: 6 months

Is the one-sided lower limit of the 95% confidence interval for the observed clinical success rate at least 80%? Clinical success of filter placement is defined as freedom from subsequent Pulmonary Embolism (PE), filter embolization, caval occlusion, filter and procedure related death, insertion adverse events (AEs), and technical failure of placement.

Technical Success of Retrieval

时间窗: 24 months

Technical success for retrieval is defined as retrieval of the filter such that the entire filter is retrieved intact.

Clinical Success of Retrieval

时间窗: 24 months

Clinical success for retrieval is defined as successful technical retrieval of the filter without retrieval complications requiring intervention. Only the 121 successful retrievals are counted here.

次要结局

  • Rate of Recurring Pulmonary Embolism(24 months)
  • Rate of New or Worsening Deep Vein Thrombosis(6 months)
  • Filter Fracture(6 months)
  • Filter Migration(6 months)
  • Filter Tilt at Placement(Post-placement imaging)
  • Filter Tilt at Retrieval(Pre-retrieval imaging)
  • Filter Penetration >3mm at Placement(Post-placement)
  • Filter Penetration >3mm at Retrieval(Pre-retrieval)

研究者

发起方
C. R. Bard
申办方类型
Industry
责任方
Sponsor

研究点 (44)

Loading locations...

相似试验